Biosimilar Newsletter Archive
-
01.04.24 -- Gliding Towards De-Risked Combination Product Development
1/4/2024
01/04/24 Biosimilar Development Newsletter
-
12.21.23 -- Do End-To-End C(x)DMOs Really Exist?
12/21/2023
12/21/23 Biosimilar Development Newsletter
-
12.14.23 -- Advancing Process Understanding Through Simulation And Digital Transformation
12/14/2023
12/14/23 Biosimilar Development Newsletter
-
12.14.23 -- FDA Sets Recommendations For Predicting Nitrosamine Impurities
12/14/2023
12/14/23 Biosimilar Development Newsletter
-
12.13.23 -- Develop Efficient Hydrophobic Interaction Chromatography (HIC) Processes
12/13/2023
12/13/23 Biosimilar Development Newsletter
-
12.08.23 -- TEST BIOS Custom Newsletter
12/8/2023
12/08/23 Biosimilar Development Newsletter
-
12.08.23 -- TEST BIOS Editorial
12/8/2023
12/08/23 Biosimilar Development Newsletter
-
12.07.23 -- FDA Warning Letters Dipped, But Don't Get Cozy
12/7/2023
12/07/23 Biosimilar Development Newsletter
-
11.30.23 -- Sandoz launches Hyrimoz (adalimumab) High-Concentration Formulation In Europe
11/30/2023
11/30/23 Biosimilar Development Newsletter
-
11.22.23 -- Preformulation Of Excipients In Biologics Development
11/22/2023
11/22/23 Biosimilar Development Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more